NASDAQ: ARQTArcutis Biotherapeutics Inc Stock Ownership - Who owns Arcutis Biotherapeutics?
Insider buying vs selling
Have Arcutis Biotherapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Masaru Matsuda | Reporting Persons title Senior Vice President and General Counsel | 2024-03-04 | 3,760 | $11.12 | $41.81kSell |
| Patrick Burnett | Reporting Persons title Senior Vice President Chief Medical Officer | 2024-03-04 | 4,782 | $11.12 | $53.18kSell |
| Patrick J. Heron | Director | 2024-03-04 | 21,052 | $9.50 | $199.99kBuy |
| Todd Franklin Watanabe | Reporting Persons title President and Chief Executive Officer | 2024-03-04 | 14,903 | $11.12 | $165.74kSell |
| Matthew Richard Moore | SVP and Chief Business Officer | 2024-03-04 | 3,468 | $11.12 | $38.57kSell |
| Todd Franklin Watanabe | Reporting Persons title President and Chief Executive Officer | 2024-02-28 | 2,465 | $10.60 | $26.13kSell |
| Patrick Burnett | Reporting Persons title Senior Vice President Chief Medical Officer | 2024-01-02 | 1,325 | $3.54 | $4.69kSell |
| Todd Franklin Watanabe | Reporting Persons title President and CEO. | 2023-12-01 | 59,525 | $1.68 | $100.06kBuy |
| Masaru Matsuda | Reporting Persons title Senior Vice President and General Counsel | 2023-11-21 | 1,850 | $1.98 | $3.66kSell |
| Frazier Life Sciences Viii LP | 10% Owner | 2023-10-24 | 80,000 | $2.50 | $200.00kBuy |
ARQT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ARQT insiders and whales buy or sell their stock.
ARQT Shareholders
What type of owners hold Arcutis Biotherapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Patrick J. Heron | 20.00% | 19,360,456 | $169.21M | Insider |
| Jennison Associates LLC | 9.36% | 9,066,082 | $79.24M | Institution |
| Frazier Life Sciences Viii LP | 9.13% | 8,838,534 | $77.25M | Insider |
| Frazier Life Sciences Management LP | 9.05% | 8,764,232 | $76.60M | Institution |
| Suvretta Capital Management LLC | 8.75% | 8,473,101 | $74.05M | Institution |
| Rubric Capital Management LP | 6.86% | 6,644,530 | $58.07M | Institution |
| Polar Capital Holdings PLC | 6.50% | 6,297,688 | $55.04M | Institution |
| Morgan Stanley | 6.28% | 6,083,072 | $53.17M | Institution |
| Blackrock Inc | 6.11% | 5,916,546 | $51.71M | Institution |
| Vanguard Group Inc | 5.06% | 4,896,513 | $42.80M | Institution |
ARQT vs Biotech Stocks
Arcutis Biotherapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.